First Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)

Ayhan, A.2024-05-202024-05-2020230923-7534http://hdl.handle.net/11727/12121enginfo:eu-repo/semantics/closedAccessFirst Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)conferenceObject34Supplement 2S511S5120010874802010881569-8041